SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cemtrex, Inc. engages in the provision of solutions in the technology industry. It operates through the following segments: Security, Industrial Services, and Cemtrex Corporate. The Security segment provides end-to-end security solutions to meet corporate, industrial, and governmental security challenges. The Industrial Services segment offers single-source expertise and services for rigging, millwrighting, in plant maintenance, equipment erection, relocation, and disassembly to diversified customers. The Cemtrex Corporate segment refers to the holding company of the other two segments. The company was founded on April 27, 1998 and is headquartered in Hauppauge, NY.

Cemtrex Inc.

Cemtrex ($CETX) is trending due to a massive premarket surge and multiple trading halts, sparking high volatility. Community chatter revolves around a potential short squeeze reminiscent of $SMX and predictions of continued upward momentum, with some suggesting extremely high price targets. The stock's nano float and recent acquisition news are also fueling the discussion.

Treasure Global, Inc. engages in the provision of payment solutions. The firm created an online-to-offline (O2O) e-commerce platform business model offering consumers and merchants instant rebates and affiliate cashback programs. It operates through the ZCITY Platform and Customized Software Development Service segments. The company was founded by Kok Pin Tan on March 20, 2020 and is headquartered in New York, NY.

Treasure Global Inc

Treasure Global is trending due to a recent revenue target update and chatter around its low float, sparking comparisons to other high-flying stocks like $SMX. Community members are actively discussing the potential for a significant short squeeze, citing high borrow rates and limited share availability. Some investors believe the stock could reach new highs, while others caution about the risks associated with low-float stocks and potential dilution.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is trending after reporting positive early-stage clinical data for its obesity drug, showing fat loss without muscle loss. The community is discussing the implications of these results, with some speculating about a potential buyout and others pointing out similarities to GLP-1 drugs. Overall sentiment is optimistic, though some caution against over-enthusiasm due to the early stage of the data.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VKTX is trending as investors debate the impact of competitor GPCR's data, particularly focusing on the lack of safety data released and potential implications for Viking's market position. Community discussions revolve around potential partnerships or a buyout, with some emphasizing Viking's strong pipeline and advanced stage in development. There is also ongoing speculation about the possibility of VK2809 skipping Phase 3 trials based on new FDA guidance.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending due to its impending inclusion in the S&P 500, driving significant after-hours price movement. While some investors celebrate the milestone and anticipate further gains, others express concerns about the company's fundamentals and accounting practices, suggesting a potential "sell the news" event. Community discussions revolve around whether the stock is overvalued and if a substantial correction is on the horizon.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its potential for a low-float squeeze, drawing comparisons to recent runners in the same sector like $SMX. The community is analyzing the stock's float and short borrow fee, with some expressing caution due to a recent offering and warrant dilution. Overall, the focus remains on whether it can achieve a similar explosive move based on its low float.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery ($WBD) is trending amid a potential takeover, with Paramount ($PARA) launching a hostile bid, challenging Netflix's ($NFLX) deal and igniting a bidding war. Community discussion revolves around the merits of each offer, regulatory hurdles, and potential outcomes for shareholders. The stock has seen significant gains YTD, fueled by M&A rumors and speculation.

PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. It is involved in the production and commercialization of topical skincare products that contain its proprietary stem cell-derived Elevai Exosomes. The company was founded by Hatem Abou-Sayed, Braeden William Lichti, and Jordan R. Plews on June 9, 2020 and is headquartered in Newport Beach, CA.

PMGC Holdings Inc

PMGC Holdings Inc.

ELAB is trending due to a premarket surge, fueled by retail trader interest in PMGC Holdings' shift towards biotech and industrial sectors. Community discussions revolve around the stock's low float and potential for a squeeze, while some traders are pointing to possible overextension. The stock's volatility and previous reverse splits are also being discussed.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending following Phase 2 data highlighting weight loss percentages, though some investors are wary due to the omission of certain safety data in the initial report. The community is actively discussing the tolerability of the drug, particularly regarding liver enzyme elevations and adverse events like vomiting, while also speculating about potential short squeezes and comparisons to competitors like $LLY and $VKTX. Some see it as a potential acquisition target in the competitive GLP-1 space.

Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015, and is headquartered in Cambridge, MA.

Fulcrum Therapeutics Inc

Fulcrum Therapeutics is trending due to positive initial Phase 1b trial results for its sickle cell disease drug, Pociredir, sparking target price hikes. Community discussions focus on the drug's potential efficacy and clean safety profile, especially regarding increased fetal hemoglobin levels. The broader context includes the promising outlook for oral treatments in sickle cell disease and Fulcrum's potential as a leader in the field.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NGENF ASIA summary 
 
 •  Company is in active discussions with FDA about breakthrough and/or accelerated approval 
 • Next trial: Planning a large, multi-site, function-focused pivotal trial (effectively phase 3) starting ~summer 2026, with up to ~60 sites worldwide. 
 • Endpoint strategy: Phase 1b/2a was biologic proof-of-concept (MEP + safety); the pivotal trial will be built around functional recovery and independence (e.g., GRASSP), with MEP as a key biomarker. 
 • NVG-291 is framed as a neurotrauma platform (SCI first, but also MS/stroke/ALS-relevant)

Nick Ferris

NVG291Fan

Steven Craig

Reginald Bell

Peter Shick

David Bonanno

Aurinia Beach

Tarquin. W Jones

Dominic desrosiers

Sean Beasley

John Doe

Broc Segura

Tim Fris

$NGENF accurate summary.one interesting point - I pay attention to phrasing, terms used - to see if there&#39;s any tell beyond what is stated. Two observations:
1)  CEO took time to explain the increased rigor associated with climbing the ladder of FDA designations, alluding this being a hot current topic, punctuating with &#39;having active discussions with the FDA on these points&#39; right now. My take - he&#39;s expecting BTD, and believes AA is more than viable.
2) in thanking all participants, clinicians and Dr Perez for their support in the study, he continually referenced the CONNECt study in the past tense -multiple times.  As a listener, it would sound as if it&#39;s completed. My take - strikes me he wouldn&#39;t reference it as such if the study were still enrolling with a distance to go. My guess is that we won&#39;t hear LPE, may not hear LPLV. Possible the end of the trial is closer than we think.

StockTwits For Android 

StockTwits Web

NervGen Pharma Corp

 ASIA summary 
 
 •  Company is in active discussions with FDA about breakthrough and/or accelerated approval 
 • Next trial: Planning a large, multi-site, function-focused pivotal trial (effectively phase 3) starting ~summer 2026, with up to ~60 sites worldwide. 
 • Endpoint strategy: Phase 1b/2a was biologic proof-of-concept (MEP + safety); the pivotal trial will be built around functional recovery and independence (e.g., GRASSP), with MEP as a key biomarker. 
 • NVG-291 is framed as a neurotrauma platform (SCI first, but also MS/stroke/ALS-relevant)

StockTwits for iOS

Mammazallata

@aladdinscarpet I wish they cold find a way to do a N=3 exploratory trial in some of these other indications, MS, ALS, and ALZ. Grants or something along those lines, just to get in human data.

Dave

Zeke Balderdash

 I wish they cold find a way to do a N=3 exploratory trial in some of these other indications, MS, ALS, and ALZ. Grants or something along those lines, just to get in human data.

@aladdinscarpet The functional recovery as the new primary endpoint is actually concerning to me. SRAL is supposedly the world leaders in rehabilitation, and even though we’ve heard second-hand that the rehabilitation wasn’t that intense, we’ve also discussed the role it may have played in the observed, measurable functional recovery. What rehabilitation equipment, care, and expertise will these other 59 centers offer? Now that it is our primary endpoint, it’s going to increase outcome variability to some degree. Do we have the “margin” in our current GRASSP results to absorb that delta and still prove a benefit? Personally, I doubt it without increasing the trial duration.

Look at the two recent AbbVie and Mitsubishi SCI trials for their similar mAb’s. ~60 sites worldwide and results keep getting pushed out. We haven’t heard ANYTHING about them, and they’re overdue. It’s sad, but I’m not expecting much from them…. MEP as a biological surrogate endpoint is still desirable IMO.

 The functional recovery as the new primary endpoint is actually concerning to me. SRAL is supposedly the world leaders in rehabilitation, and even though we’ve heard second-hand that the rehabilitation wasn’t that intense, we’ve also discussed the role it may have played in the observed, measurable functional recovery. What rehabilitation equipment, care, and expertise will these other 59 centers offer? Now that it is our primary endpoint, it’s going to increase outcome variability to some degree. Do we have the “margin” in our current GRASSP results to absorb that delta and still prove a benefit? Personally, I doubt it without increasing the trial duration.

Look at the two recent AbbVie and Mitsubishi SCI trials for their similar mAb’s. ~60 sites worldwide and results keep getting pushed out. We haven’t heard ANYTHING about them, and they’re overdue. It’s sad, but I’m not expecting much from them…. MEP as a biological surrogate endpoint is still desirable IMO.

@Mammazallata Getting in front of KOL’s and potential Ph3 study participants. ymmv.

 Getting in front of KOL’s and potential Ph3 study participants. ymmv.